24 November 2017
News and Views
Links and Services
This week's publication of the New England Journal of Medicine reports on the safety, activity, and immune correlates of anti–programmed death-1 antibody in cancer.
Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors